1. ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R‐CHOP) FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (12th June 2019) Authors: Cummin, T.E.; Caddy, J.; Mercer, K.; Maishman, T.; Schuh, A.; Lopez Pascua, L.; Collins, G.; McMillan, A.; Ardeshna, K.; Galanopoulous, A.; Burton, C.; Barrans, S.; Griffiths, G.; Johnson, P.; Davies, A.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Novel Casein Kinase II (CK2) inhibitor BMS-135 shows significant in vivo anti-leukemia effect. (October 2022) Authors: Gowda, C.; Purandare, A.; Mercer, K.; Duke, K.; Dovat, S. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗